NASDAQ:SLS SELLAS Life Sciences Group Q3 2026 Earnings Date & Estimates $10.15 -0.23 (-2.22%) Closing price 10/29/2026 04:00 PM EasternExtended Trading$9.96 -0.20 (-1.92%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. SELLAS Life Sciences Group is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, after market closes. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 18, 2026TimeAfter Market ClosesConference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from SELLAS Life Sciences Group in Q3 2026SELLAS Life Sciences Group is expected to post earnings of -$0.05 per share. In the same quarter a year earlier SELLAS Life Sciences Group reported -$0.06 per share. SELLAS Life Sciences Group last reported on August 11, 2026, posting -$0.05 per share and missing the -$0.0450 consensus estimate. SELLAS Life Sciences Group has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.05Prior-Year EPS-$0.06Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.05 (Missed by -$0.0050)EPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report SELLAS Life Sciences Group Q3 2026 Earnings FAQ When does SELLAS Life Sciences Group report Q3 2026 earnings? SELLAS Life Sciences Group (NASDAQ:SLS) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is SELLAS Life Sciences Group's Q3 2026 earnings call? SELLAS Life Sciences Group's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for SELLAS Life Sciences Group? Analysts expect SELLAS Life Sciences Group to post earnings of -$0.05 per share for Q3 2026. SELLAS Life Sciences Group Earnings HeadlinesSELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?October 29 at 8:30 PM | finance.yahoo.comSellas Sinks 18% as Phase 3 Leukemia Trial Reaches “Critical Milestone” Ahead of Final DataOctober 28 at 12:38 PM | finance.yahoo.comWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 30 at 1:00 AM | Brownstone Research (Ad)Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL FailureOctober 28 at 12:38 PM | seekingalpha.comSELLAS Life Sciences Stock Falls 17% After Announcement Of Phase 3 REGAL Trial MilestoneOctober 28 at 12:38 PM | rttnews.comSellas falls as REGAL trial nears final analysisOctober 28 at 12:38 PM | seekingalpha.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies. SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer. GPS has been evaluated in clinical studies involving acute myeloid leukemia (AML) and other malignancies. The company is also developing SLS009, an oral, highly selective cyclin-dependent kinase 9 (CDK9) inhibitor being investigated for potential use in patients with blood cancers, including AML. The company’s programs remain in clinical development and are being evaluated through trials conducted with research and medical partners. SELLAS is headquartered in New York. Angelos M. Stergiou, M.D., Sc.D., has served as the company’s president and chief executive officer and is a member of its board of directors.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
